Syros Pharmaceuticals, Inc. (SYRS) Financials
SYRS Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 168.2 million | 151.5 million |
2023-09-30 | 147.8 million | 111.5 million |
2023-06-30 | 181.0 million | 107.7 million |
2023-03-31 | 205.3 million | 98.6 million |
SYRS Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -18.6 million | 1.7 million |
2023-09-30 | -31.9 million | 3.3 million |
2023-06-30 | -22.4 million | 2.8 million |
2023-03-31 | -37.1 million | 2.6 million |
SYRS Net Income
No data available :(
SYRS Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 139.5 million | - | 20.9 million |
2023-09-30 | 112.2 million | - | 21.4 million |
2023-06-30 | 144.0 million | - | 21.9 million |
2023-03-31 | 165.8 million | 39.1 million | 22.4 million |
SYRS Shares Outstanding
SYRS Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 38000 | 21.2 million | 5.9 million | - |
2023-09-30 | - | 28.3 million | 7.8 million | - |
2023-06-30 | 1000 | 29.6 million | 7.2 million | - |
2023-03-31 | 235000 | 28.8 million | 7.4 million | - |
SYRS Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 386000 | 279000 |
2023-09-30 | 3.8 million | 616000 |
2023-06-30 | 2.8 million | 653000 |
2023-03-31 | 3.0 million | 704000 |
SYRS
Price: $5
52 week price:
Earnings Per Share: 0.85 USD
P/E Ratio: 8.42
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 234220
Ebitda: -13.6 millionMarket Capitalization: 137.1 million